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abstract
 
Na
 
 
 
 channel blockers such as ﬂecainide have found renewed usefulness in the diagnosis and treat-
 
ment of two clinical syndromes arising from inherited mutations in SCN5A, the gene encoding the 
 
 
 
 subunit of the
cardiac voltage–gated Na
 
 
 
 channel. The Brugada syndrome (BrS) and the LQT-3 variant of the Long QT syndrome
are caused by disease-linked SCN5A mutations that act to change functional and pharmacological properties of the
channel. Here we have explored a set of SCN5A mutations linked both to BrS and LQT-3 to determine what disease-
modiﬁed channel properties underlie distinct responses to the Na
 
 
 
 channel blocker ﬂecainide. We focused on
ﬂecainide block that develops with repetitive channel activity, so-called use-dependent block (UDB). Our results in-
dicate that mutation-induced changes in the voltage-dependence of channel availability (inactivation) may act as
determinants of ﬂecainide block. The data further indicate that UDB by ﬂecainide requires channel opening, but is
not likely due to open channel block. Rather, ﬂecainide appears to interact with inactivation states that follow depo-
larization-induced channel opening, and mutation-induced changes in channel inactivation will alter ﬂecainide
block independent of the disease to which the mutation is linked. Analysis of ﬂecainide block of mutant channels
linked to these rare disorders has provided novel insight into the molecular determinants of drug action.
 
INTRODUCTION
 
Local anesthetic molecules such as lidocaine and
 
ﬂecainide block Na
 
 
 
 channels and have been used
therapeutically to manage cardiac arrhythmias (Rosen
et al., 1975; Rosen and Wit, 1983; Wit and Rosen,
1983). Despite the prospective therapeutic value of the
inherent voltage- and use-dependent properties of
 
channel block by these drugs in the treatment of tachy-
arrhythmias, their potential has been overshadowed
by toxic side effects (Rosen and Wit, 1987; Weissen-
burger et al., 1991). Recently however, Na
 
 
 
 channel
blockers have again proven useful for diagnosis and
treatment of Brugada and LQT-3 syndromes, two inher-
ited diseases linked to mutations in SCN5A, the gene
that encodes the 
 
 
 
 subunit of the cardiac voltage–gated
Na
 
 
 
 channel (Brugada et al., 1999). Na
 
 
 
 channel
blockade by the ﬂecainide is of particular interest as it
had been shown to reduce QT prolongation in carriers
of some LQT-3 mutations (Brugada et al., 1999), and
(Benhorin et al., 2000; Windle et al., 2001)and to evoke
ST segment elevation, a hallmark of the Brugada syn-
drome (BrS),* in patients with a predisposition to the
disease (Brugada et al., 2000). Thus, in the case of
LQT-3, ﬂecainide has potential therapeutic applica-
 
tion, whereas for BrS it has proven useful as a diagnos-
tic tool. However, in some cases, ﬂecainide has been
 
reported to provoke BrS symptoms (ST segment ele-
vation) in patients carrying LQT-3 mutations (Priori
et al., 2000). Furthermore, ﬂecainide preferentially
blocks some LQT-3 or BrS-linked mutant Na
 
 
 
 channels
(Abriel et al., 2000; Grant et al., 2000; Nagatomo et al.,
2000; Viswanathan et al., 2001). Investigation of the
drug interaction with these and other LQT-3– and BrS-
linked mutations may indicate the usefulness of ﬂecain-
ide in the detection and management of these disor-
ders and in determining whether or not it is reasonable
to use this drug to identify potential disease-speciﬁc
mutations. Moreover, exploration of the relationship
between altered channel structure and drug efﬁcacy
 
can provide new insight into molecular determinants
of ﬂecainide block of the human cardiac sodium
channel.
 
Local anesthetic compounds, such as lidocaine and
 
ﬂecainide, block Na
 
 
 
 channels in a use- and voltage-
 
dependent manner. These actions have been widely inter-
preted within the framework of the modulated receptor
hypothesis that ion channel states can alter drug afﬁnity
and that charged and neutral drugs interact with a com-
mon receptor but gain access to it via distinct hydro-
phobic and hydrophilic pathways (Hille, 1977a; Honde-
ghem and Katzung, 1977). Use-dependent block by
ﬂecainide, but not lidocaine, depends critically on
channel openings (Ragsdale et al., 1994; Qu et al.,
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1995), suggesting that ﬂecainide preferentially blocks
channels in the open state. Use-dependent block
(UDB) by lidocaine has been more closely related to
the inactivated state of the channel (Bean et al., 1983).
The precise mechanism underlying this difference is
not clear; however, it is very likely related to the inﬂu-
ence of drug charge on access to receptor site(s) on the
channel (Strichartz, 1973; Hille, 1977a; Chernoff and
Strichartz, 1990). Lidocaine has a pKa of 7.6–8.0 and thus
may be up to 50% neutral at physiologic pH, and
ﬂecainide has a pKa of 
 
 
 
9.3 leaving 
 
 
 
1% neutral at pH
7.4 (Hille, 1977b; Strichartz et al., 1990). Thus, the
drug charge might be an important determinant of
its state speciﬁcity of Na
 
 
 
 channel blockade as well as
its distinct kinetic properties (Strichartz, 1973; Hille,
1977a; Chernoff and Strichartz, 1990).
The results of our work indicate that ﬂecainide block
that develops with repetitive channel activity, so-called
UDB indeed requires channel opening. However, the
efﬁcacy of drug action is critically related to inactiva-
tion that occurs subsequent to channel opening (Fig.
1). Several recent studies have suggested that interme-
diate inactivation state conformations can be arrived at
by closed state inactivation pathways or via channel
opening–induced inactivation (Kambouris et al., 2000;
Ong et al., 2000; Wang et al., 2000). Our data support a
role of inactivation in ﬂecainide UDB, but suggest that
channel opening is required so that ﬂecainide may
gain access to the site of action. These sites are altered
in their voltage dependence compared with wild-type
(WT) in the steady-state that is reﬂected in the channel
availability curve, an indicator of inactivation from
closed states. Our results predict, and we conﬁrm, that
 
mutations that alter the voltage-dependence of channel
inactivation will alter ﬂecainide UDB and that the efﬁ-
cacy of ﬂecainide in treating inherited arrhythmias due
to SCN5A mutations will depend critically on the ef-
fects of the mutations on the voltage-dependence of
channel inactivation. Further, our data clearly show
that these mutation-induced changes of gating deter-
mine drug action independent of the disease (BrS or
LQT-3) to which the mutation is linked and thus indi-
cate that ﬂecainide block cannot be used to discrimi-
nate between BrS and LQT-3 mutant channels.
 
MATERIALS AND METHODS
 
Mutagenesis and Expression of Recombinant Na
 
 
 
 Channels
 
Mutations of 
 
SCN5A
 
 were engineered into WT cDNA cloned in
pcDNA3.1 (Invitrogen) by overlap extension using mutation-spe-
ciﬁc primers and Quick Change site-directed mutagenesis kit
(Stratagene) as described previously (Abriel et al., 2001). The
presence of the mutation was conﬁrmed by sequence analysis. WT
and mutant Na
 
 
 
 channels were expressed in HEK293 cells as pre-
viously described (Abriel et al., 2001). Transient transfections
were performed with equal amounts of Na
 
 
 
 channel 
 
 
 
 subunit
and with h
 
 
 
1
 
, subcloned individually into the pcDNA3.1 (Invitro-
gen) vector (total cDNA 2.5 
 
 
 
g) using a previously described lipo-
fection procedure (Abriel et al., 2001). Expression of channels
was studied using patch clamp procedures 48 h after transfection.
 
Electrophysiology
 
Membrane currents were measured using whole cell patch-clamp
procedures with Axopatch 200B ampliﬁers (Axon Instruments,
Inc.). Recordings were made at room temperature (22
 
 
 
C). The in-
ternal pipette solution contained (in mmol/L): aspartic acid 50,
CsCl 60, Na
 
2
 
-ATP 5, EGTA 11, HEPES 10, CaCl
 
2
 
 1, and MgCl
 
2
 
 1,
with pH 7.4 adjusted with CsOH[[ (Abriel et al., 2001). External
solutions consisted of (mmol/L) NaCl 130, CaCl
 
2
 
 2, CsCl 5, MgCl
 
2
 
1.2, HEPES 10, and glucose 5, with pH 7.4 adjusted with CsOH. In
experiments designed to measure the voltage dependence of acti-
vation, external Na
 
 
 
 was reduced to 30 mM using n-methyl-glu-
camine as an Na
 
 
 
 substitute. Activation curves were determined
by normalization of peak current vs. voltage to driving force deter-
mined as the difference between test voltage and measured chan-
nel reversal potential in low external Na
 
 
 
. UDB was induced by
imposing conditioning trains of 100–300 pulses (
 
 
 
10 mV, 25 ms)
from a 
 
 
 
100 mV holding potential (HP) (unless otherwise speci-
ﬁed) at frequencies between 1 and 10 Hz. This was sufﬁciently
long to induce steady-state UDB for each construct. UDB was
measured as the ratio of peak current at 
 
 
 
10 mV after and before
application of a conditioning train and is reported as the percent-
age block of peak current.
Protocols for measuring the time course of recovery from, and
isochronal availability after, ﬂecainide block were as follows.
Flecainide block of channels was induced by application of a con-
ditioning train (see above) such that 
 
 
 
90% of channel activity was
blocked. Then, for isochronal availability, a 500-ms pulse was ap-
plied to a conditioning voltage followed by measurement of cur-
rent in response to a pulse to 
 
 
 
10 mV. After a 10-s pulse-free in-
terval at the holding potential, the trial was repeated, channel
block was induced by the conditioning train, and a 500-ms condi-
tioning pulse was imposed to a different voltage. In the case of the
time course of recovery from drug block, a similar voltage trial was
followed, but in this case, after application of the conditioning
Figure 1. Modulated receptor scheme for preferential drug bind-
ing to inactivated or open channels. R is the rested, O the open, and
I the inactivated states of drug-free Na  channels; RD, OD, and ID
are representative states for drug-associated Na  channels. 
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train to block channels, current was measured in response to a
 
 
 
10-mV test pulse applied after a variable pulse-free interval at
the holding potential. As above, voltage trials were separated by
10-s pulse-free intervals at the holding potential, and each trial
consisted of application of a pulse train to induce channel block.
Pclamp 8.0 (Axon Instruments, Inc.), Excel (Microsoft), and
Origin (Microcal Software) were used for data acquisition and
analysis. Data are presented as mean values 
 
 
 
 SEM. 
 
P
 
 
 
  
 
0.05 was
considered statistically signiﬁcant (using Student’s 
 
t
 
 test).
 
RESULTS
 
LQT-3 and BrS Mutations Alter Sensitivity to UDB by Flecainide
 
We have demonstrated previously that LQT-3 D1790G
mutant channels are more sensitive than WT channels
to UDB by ﬂecainide (Abriel et al., 2000). To deter-
mine whether this altered sensitivity was due to muta-
tion-induced changes in COOH-terminal structure or
channel gating, we compared ﬂecainide-induced UDB
of three previously described COOH-terminal dis-
ease-linked mutant channels (D1790G, Y1795C, and
Y1795H) with distinct biophysical phenotypes (An et
al., 1998; Rivolta et al., 2001). Fig. 2 A illustrates this
measurement for each construct and shows the super-
imposition of current (at 
 
 
 
10 mV) before and after
(arrows) a 1-Hz conditioning voltage pulse train in the
presence of ﬂecainide (10 
 
 
 
M). At this frequency, as is
evident by the arrows in the ﬁgure, the inherited
COOH-terminal mutations confer differing sensitivities
to UDB by ﬂecainide. This point is substantiated over a
range of conditioning pulse frequencies (Fig. 2 B), at
Figure 2. UDB of WT and mutant Na  channels by ﬂecainide. Currents were evoked by imposing conditioning trains of 100–300 pulses
( 10 mV, 25 ms) from a holding potential of  100 mV in the presence of ﬂecainide (1  M to 1 mM) and over a frequency range of 1–10
Hz. Pulses were applied until steady-state UDB (deﬁned as the percent decrease in current after the pulse train relative to current before
the pulse train) was achieved. (A) Examples of current traces at recorded at 1 Hz for wild-type (WT), D1790G (DG), Y1795C (YC), and
Y1795H (YH) channels before and after steady-state UDB (arrows). Currents are superimposed records of ﬁrst and last (100th) pulse of a
conditioning train. (B) Percent UDB plotted vs. conditioning pulse frequency (1–10 Hz) in the presence of 10  M ﬂecainide. (C) UDB for
each construct at a ﬁxed pulse frequency (5 Hz) but over a range of ﬂecainide concentrations (1  M to 1 mM). The smooth curves are the
best ﬁts of the Hill equation 1/{1   [(drug)/EC50]n} to the data. The estimated EC50 and n values obtained from the ﬁts are 11.2   1.4
 M,  1.27  0.13 (WT); 2.8   0.4  M,  1.29  0.11 (DG); 10.8  1.4  M,  1.14   0.07 (YC), and 2.9   0.3  M,  1.17   0.09 (YH). P  
0.01 compared with WT, n   3–5 cells per measurement. 
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ﬁxed ﬂecainide concentration (10 
 
 
 
M), and at a ﬁxed
pulse frequency (5 Hz), and over a broad ﬂecainide
concentration range (Fig. 2 C). At a ﬁxed ﬂecainide
concentration (10 
 
 
 
M), 
 
 
 
30% of peak current was
blocked in a use-dependent manner for WT channels
at a conditioning pulse frequency of 1 Hz, and the
block almost doubled when the pulse frequency was in-
creased from 1 to 10 Hz (Fig. 2 B). Y1795H channels,
like D1790G channels, exhibited greater UDB than WT
channels. In fact there is no signiﬁcant difference in
the UDB of Y1795H or D1790G channels over the fre-
quency or concentration range studied, whereas, at
the same time and same range of experimental condi-
tions, frequency-dependent block of both D1790G and
Y1795H channels is signiﬁcantly greater than WT chan-
nels. In contrast, there is no signiﬁcant difference be-
tween UDB for Y1795C and WT channels over the same
range of experimental conditions. As indicated in Fig.
2 C, the estimated EC
 
50
 
 for UDB of D1790G and
Y1790H channels is approximately threefold less than
 
block of either WT or Y1975C channels. Importantly,
these data indicate that UDB of peak current by ﬂecain-
ide cannot be used to identify LQT-3 vs. BrS mutations,
as the Y1795H mutation (Rivolta et al., 2001) is linked
to BrS and the D1790G mutation is linked to LQT-3
(Benhorin et al., 1998). What properties of the mutant
channels cause these differences in sensitivity to
ﬂecainide UDB?
 
UDB by Flecainide Requires Channel Openings
 
Mutations could alter UDB during a pulse train either
by altering the amount of drug that binds to and dissoci-
ates from open or resulting inactivated channels during
the depolarizing pulses or by altering the rate at which
the drug dissociates between the pulses as the channels
return to the resting state. We reported previously that
the D1790G mutation slows the recovery from ﬂecain-
ide block at negative voltages (Abriel et al., 2000). Here,
we next sought to determine the contribution of chan-
nel openings to ﬂecainide UDB, and applied the voltage
Figure 3. Inﬂuence of inherited mutations on the voltage dependence of ﬂecainide UDB. (A) Normalized block is plotted vs. condition-
ing pulse amplitude. Currents were recorded before (control) and after (test) application of conditioning pulses (100 pulses, 25 Hz) of
varying amplitude in the absence (open symbols) and presence (ﬁlled symbols) of 10  M ﬂecainide. A 1-s interval at the holding potential
( 100 mV) was imposed between the conditioning train and test pulse to allow drug-free channels to recover from inactivation. Normal-
ized block was determined as the fraction of test pulse current (normalized to control current) reduced by the conditioning train. (B) The
voltage-dependence of channel activation (determined as in materials and methods) is shown for the four constructs investigated. n  
3–4 cells per measurement. 
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protocol illustrated in Fig. 3 for channels encoded by
each construct. Currents were measured before (con-
trol) and after (test) applying conditioning pulses (100
pulses, 25 Hz) of varying amplitude in the presence of
10 
 
 
 
M ﬂecainide, a protocol similar to that used previ-
ously by Ragsdale et al. (1996). A 1-s delay was imposed
between the conditioning train and test pulse to allow
drug-free channels to recover from inactivation that de-
veloped during the train. Normalized block was deter-
mined as the fraction of test pulse current (normalized
to control current) reduced by the conditioning train
for each construct. Normalized block was plotted vs.
conditioning pulse amplitude in Fig. 3. Drug-free cur-
rents (open symbols) are not affected by the protocol,
indicating full recovery from inactivation during the
pulse free interval at 
 
 
 
100 mV. In contrast, the condi-
tioning train induces block for each construct and the
threshold for block is near 
 
 
 
40 mV (arrow in ﬁgure).
Fig. 3 B shows activation curves for WT and the three
COOH-terminal mutant channels to conﬁrm that the
threshold for channel openings (arrow in Fig. 3 B) is vir-
tually indistinguishable from the threshold for UDB.
Importantly, there is no UDB if the conditioning volt-
ages vary from 
 
 
 
80 mV to 
 
 
 
50 mV, despite the fact that
for each of the constructs tested closed-state inactivation
channel availability changes from 100% to 0% over this
Figure 4. Single channel and averaged ensemble current properties of WT and mutant channels. Cell-attached patch recordings are
shown for WT, D1709G (DG), Y1795H (YH), and Y1795C (YC) channels. Recordings were obtained in response to test pulses ( 30 mV,
100 ms) applied at 2 Hz from  120 mV. (A) Current recordings of individual and consecutive sweeps are shown to emphasize the effects
of inherited mutations on channel opening kinetics. Ensemble currents (constructed by averaging 500 consecutive sweeps) are shown for
each construct below the individual sweeps. (B) Open time distributions of WT and mutants channels. Open time histograms were gener-
ated for each construct using 200- s bins of all events recorded from 500–1,000 sweeps. Patches used included three or fewer channels.
MOT was estimated by the best-ﬁt single exponential function to each histogram. The ﬁtted curves are illustrated as dashed lines in each
panel. The resulting MOT estimates are: 0.50   0.02 ms (WT); 0.42   0.03 ms (DG); 0.39   0.02 ms (YH); and 0.97   0.05 ms (YC); P  
0.05 for DG, YH, and YC vs. WT, respectively, n   6–7 patches per condition. (C) Time course of the onset of UDB (1 Hz, 10  M ﬂecain-
ide) during pulse trains applied to WT and YC channels. The data were normalized to the current amplitude of the ﬁrst pulse in the train
and ﬁt with a single exponential function (A   exp-t/    base), the time constant ( ) for WT and Y1795C were 45.29 s 1 and 20.09 s 1
(P   0.01 vs. WT, n   3 cells per condition).44 Flecainide Block of Mutant Heart Na  Channels
voltage range. Thus, channel openings are necessary for
ﬂecainide UDB of WT as well as D1790G, Y1795H, and
Y1795C channels. Therefore, use-dependent ﬂecainide
block does not appear to develop from the closed state,
excluding the possibility that increased closed-state inac-
tivation underlies this process (Kambouris et al., 2000;
Viswanathan et al., 2001).
Fig. 2 illustrates the effect of COOH-terminal muta-
tions on UDB, whereas Fig. 3 demonstrates the neces-
sity of channel opening for the development of this
block. To rule out the possibility that ﬂecainide UDB is
due to block of open channels, we tested the effect of
channel mean open time (MOT) on drug afﬁnity. If
ﬂecainide blocks open channels, then it follows that
Figure 5. (A) Effects of ﬂecainide on Na  channel availability of WT channels in the absence and presence of conditioning pulses. Avail-
ability curves were obtained with the pulse protocol shown in the inset in the absence and presence of a train of conditioning pulses ( 10
mV, 25 Hz, 100 pulses). Prepulses (500 ms) to a series of voltages ( 160 to  10 mV) preceded a 25-ms test pulse to  10 mV. Prepulses
were changed and the entire protocol repeated once every 10 s. Current was recorded during the test pulse and normalized to the test
pulse current recorded after the most negative prepulse. Curves were recorded in the absence of conditioning trains ( ,  ) and after con-
ditioning trains ( ,  ) in the absence (open symbols) and presence of ﬂecainide (10  M, ﬁlled symbols). The solid lines represent the
best-ﬁt Boltzmann equation (1/[1   exp(V-V1/2)/k], with the following parameters in this experiments for control and ﬂecainide, respec-
tively: in the presence of conditioning trains pulses, midpoint V1/2    73.33   3.1 and  87.43   2.55 mV, slope factor Vk   7.33   0.88
and 10.05   1.84 mV; in the absence of conditioning trains pulses, V1/2    70.46   2.44 and  72.18   3.21 mV, Vk   6.34   0.58 and 6.89
  0.77 mV; n   3–5 cells per condition. The dotted line represents the curve in the drug with conditioning train pulse scaled to control, il-
lustrating both the shift and reduced slope. (B–D) Effects of D1790G, Y1795H, and Y1795C mutations on the voltage dependence of chan-
nel availability after conditioning pulses in the presence of ﬂecainide. Availability curves for D1790G (DG), Y1795C (YC), and Y1795H
(YH) channels were obtained after conditioning pulses as described above in the absence and presence of 10  M ﬂecainide. The solid
lines represent the best-ﬁt Boltzmann equation with the following parameters for control and ﬂecainide, respectively: DG, V1/2    86.33  
2.53 mV and  142.17   8.66 mV, Vk   5.77   0.65 and 19.7   3.89 mV; YH, V1/2    89.17   5.58 and  138.11   6.45 mV, Vk   5.94  
0.78 and 14.33   2.92 mV; YC, V1/2    78.55   3.45 mV and  93.77   3.49 mV, Vk   6.32   1.18 and 9.58   0.58 mV; n   3–5 cells per
condition. In each panel the symbols are: DG ( ,  ); YC ( ,  ); and YH ( ,  ) channels. Open symbols represent drug-free and ﬁlled
symbols drug-containing conditions. The dotted lines in each panel represent the curves in the presence of drug normalized to drug-free
maximal currents.45 Liu et al.
mutation-induced changes in MOTs would be expected
to parallel mutation-induced changes in UDB (Anno
and Hondeghem, 1990). Channel mean open times are
signiﬁcantly shorter for D1790G and Y1795H, and sig-
niﬁcantly longer for Y1795C channels compared with
WT channels (Fig. 4, A and B). If ﬂecainide were to
block open channels, we would expect that D1790G
and Y1795H would exhibit less UDB than Y1795C chan-
nels. However, we ﬁnd the opposite: Y1795C are less
sensitive to ﬂecainide UDB than either Y1795H or
D1790G channels. Together, these results strongly sug-
gest that ﬂecainide requires channels to open ﬁrst in
order to bind, but is not dependent on the open state
to promote block. This possibility is further supported
by the data presented in Fig. 4 C, which compares the
time course of the onset of block for WT and Y1795C
channels. Here the development of block is clearly
faster for Y1795C channels, but the steady-state block is
the same as WT. This effect might be expected if entry
through open channels is a prerequisite for block, but
that afﬁnity of block is not determined by the open
state of the channel. Our data raise another interesting
possibility that the resulting inactivated state may be
playing an important role in ﬂecainide block.
Evidence for Interactions with Inactivated Channels
The COOH-terminal tail of the Na  channel   subunit
plays a critical role in control of inactivation (Mante-
gazza et al., 2001; Cormier et al., 2002). Point muta-
tions in the COOH terminus can shift the voltage-
dependence and alter kinetics of inactivation (An et al.,
1998; Benhorin et al., 1998; Bezzina et al., 1999; Wei et
al., 1999; Akai et al., 2000; Veldkamp et al., 2000; Ri-
volta et al., 2001). If UDB by ﬂecainide is associated
with preferential interaction with the inactivated state,
a shift in voltage-dependent availability by ﬂecainide
would be expected (Bean et al., 1983; Snyders and
Hondeghem, 1987). We therefore ﬁrst determined the
inﬂuence of ﬂecainide on WT Na  channel availability
in the absence and presence of conditioning pulses
(Fig. 5 A). Because the kinetics of drug unblock are so
slow (see below), we did not measure steady-state avail-
ability in the presence of drug. Instead, we measured
channel availability using prepulses of ﬁxed intervals
(500 ms, inset Fig. 5). Because channel openings are
required for ﬂecainide UDB, the availability curve of
drug-associated channels was measured after condition-
ing trains (protocol shown as inset Fig. 5). Both curves
were ﬁtted with Boltzmann equations to determine the
inﬂuence of ﬂecainide on the voltage for which half of
the channels are available to conduct (V1/2) and the
slope factor for the curve (Vk). Under drug-free condi-
tions, the conditioning train has only a small effect on
WT channel availability due to channel inactivation in-
duced by the conditioning pulses (Fig. 5 A,  , drug-free
no train;  , drug-free plus conditioning train). How-
ever, in the presence of ﬂecainide (10  M), channel
availability is markedly altered after ( ), but not in the
absence of conditioning pulses ( ). After condition-
ing pulses, V1/2 is shifted in the presence of ﬂecainide
in the hyperpolarizing direction ( 87.4    3.0 mV
[ﬂecainide] vs.  73.3   3.0 mV [control], n   5, P  
0.01) and Vk is reduced (10.1   2.0 mV [control] vs. 7.3  
1.0 mV [ﬂecainide], P   0.01). Normalization of the
availability curves in the presence of ﬂecainide (dotted
curves, Fig. 5 A) clearly shows the effect of the drug on
the voltage-dependence of channel availability, similar
to the effects of both ﬂecainide and quinidine on na-
tive Na  channels in guinea pig myocytes (Anno and
Hondeghem, 1990; Snyders and Hondeghem, 1990).
Together, these results are consistent with preferential
ﬂecainide block of inactivated channels, but only after
channels are opened during the conditioning train.
Altered Channel Availability Alters Flecainide Block
These results suggest that mutations that affect the volt-
age-dependence of channel availability may inﬂuence
ﬂecainide block through interactions with inactivated
channels. We took advantage of the effects of the
D1790G, Y1795H, and Y1795C mutations on the volt-
age-dependence of channel availability (An et al., 1998;
Rivolta et al., 2001) to test this prediction. Fig. 5, B–D,
summarizes these experiments and shows strong corre-
lation between mutation-induced changes in drug-free
availability and the voltage-dependence of channel
availability in the presence of drug. In the case of the
Y1795C mutation, which has little effect on the voltage-
dependence of inactivation compared with WT chan-
nels (compare open triangles, Fig. 5 C, with open cir-
cles, Fig. 5 A), ﬂecainide-altered availability is virtually
identical to ﬂecainide-altered availability of WT chan-
nels. However, in the case of both D1790G and Y1795H
channels, which shift inactivation of drug-free channels
in the hyperpolarizing direction (compare open cir-
cles, Fig. 5 B, and triangles, Fig. 5 D, with open circles,
Fig. 5 A), the channel availability curve is markedly
shifted to more negative voltages after conditioning
pulses in the presence of drug. Furthermore, after nor-
malization (dotted curves, Fig. 5, B and D) and estima-
tion of Boltzmann parameters for availability in the
presence of ﬂecainide, it is clear that channel availabil-
ity in the presence of ﬂecainide is approximately the
same for both mutations.
The ﬂecainide-altered availability curves presented in
Fig. 5 reﬂect mutation-induced differences in the num-
ber of channels that recover from drug-block for ﬁxed
time periods (500 ms) at different conditioning volt-
ages. Hence, these curves may be considered isochro-
nal (500 ms) for recovery from block and inactiva-
tion rather than true steady-state availability curves in46 Flecainide Block of Mutant Heart Na  Channels
the presence of drug, and the parameters describing
the curves (see Table I) only estimate channel availabil-
ity in the presence of drug.
To estimate more accurately times needed for steady-
state recovery from drug block, we next measured the
time course of recovery from UDB by ﬂecainide for WT
and the three mutant channel constructs. In these ex-
periments, we applied a conditioning train of pulses for
a ﬁxed duration and frequency to induce ﬂecainide
block of channels. As illustrated in Fig. 6, in the ab-
sence of drug two components of recovery were appar-
ent, with  75% of the recovery occurring within 100
ms for both WT and mutant channels. This is consis-
tent with rapid recovery from inactivation of unblocked
channels. In the presence of ﬂecainide, the recovery of
functional channels is very different: D1790G (DG)
and Y1795H (YH) channels recover very slowly. Even at
10 s at the holding potential ( 100 mV) under pulse-
free conditions, only a small fraction of the ﬂecainide-
blocked current recovers. The slower recovery kinetics
for drug-bound DG and YH channels are consistent
with enhanced UDB found for these mutants.
To determine whether or not both WT and mutant
channels eventually recovery fully from drug block,
even in the absence of channel openings, we further
measured the recovery from UDB for WT and DG
Figure 6. Recovery from ﬂecainide block of WT, D1790G, Y1795H, and Y1795C channels. UDB was induced by trains of 100 pulses ( 10
mV, 25 ms, 25 Hz) from a  100 mV holding potential. Test pulses were then imposed after variable recovery intervals at  100 mV. Cur-
rents were normalized to steady-state current levels during slow pacing (once every 30 s) and plotted against recovery interval in the ab-
sence and presence of ﬂecainide (10  M). The averaged data were ﬁtted with a two exponential function: y(t)  y0   A1   exp-t/ 1   A2  
exp-t/ 2), where t is the recovery time,  1 and  2 are the recovery time constant, A1 and A2 are fractional amplitudes of each component,
and y0 is the estimated steady-state fraction of recovered current. The ﬁtting parameters are shown in Table I. In each panel the symbols
are: WT ( ,  ), DG ( ,  ), YH ( ,  ) and YC ( ,  ) channels. Open symbols represent drug-free and ﬁlled symbols drug-containing
conditions. n   3–5 cells per condition.47 Liu et al.
channels over extremely long pulse-free intervals at
 120 mV. These data, summarized in Fig. 7, indicate
that after extremely long periods (100 s) at this voltage,
even DG channels recover from UDB.
We then ﬁt the data summarized in Fig. 6 with func-
tions containing two exponential components under
two different conditions. First, we allowed the ﬁtting
routine (materials and methods) to vary not only the
time constants and relative amplitudes of the two expo-
nential components, but also the estimated steady-state
fraction of current that recovers. Because the recovery
process is so slow (Fig. 7) over the limited time course
of the experiments in Fig. 6, this method underesti-
mates the total fraction of recovered current and hence
also underestimates any slow time constant of recovery
that may contribute to this process. In a second ap-
proach, we took the data of Fig. 7 and assumed that,
given enough time, all channels would eventually re-
cover so the steady-state fraction of recovered current
was set to 1 and ﬁxed in the ﬁtting routine. This proce-
dure results in estimates of slow time constants that are
much longer than those obtained with the former
methodology, but based on the data of Fig. 7, are likely
to be a more accurate estimation. The data summa-
rized in Table I provide a range of time constants for
recovery from block which shows a clear mutation-
induced slowing of the recovery from drug block that is
most pronounced for YH and DG channels. Again, this
very slow recovery precludes quantitative measurement
of the voltage-dependence of steady-state inactivation
in our cells (Fig. 5), but it does allow us to analyze the
recovery data in two ways (see Table I). In the ﬁrst row,
corresponding to ﬂecainide block, are functions ﬁt to
the actual data in Fig. 7 (where we allow the ﬁtting rou-
tine to extrapolate the fraction of steady-state recov-
ered current. We have also included (next row) the ﬁts
to data assuming complete recovery from block (equi-
librium value   1), which we believe reﬂects true
steady-state conditions. In either case, the results show
clear mutation-induced slowing of recovery that paral-
lels the mutation-induced shifts of drug-free availability
(Table II).
These data are consistent with the modulated recep-
tor framework in which drug-bound channels transi-
tion from a high afﬁnity–inactivated state to a lower af-
ﬁnity drug-bound and rested state from which drug dis-
Figure 7. Very slow recovery from ﬂecainide block of WT and D1790G channels. UDB of WT and D1790G channels was induced by
trains of 100 pulses ( 10 mV, 25 ms, 25 Hz) from a  100 mV holding potential. Test pulses were then imposed after variable recovery in-
tervals at  120 mV. Currents were normalized to steady-state current levels during slow pacing (once every 30 s) and plotted against recov-
ery interval in the absence and presence of ﬂecainide (30  M). In both panels the symbols are: WT ( ,  ); D1790G ( ,  ); open symbols
represent drug-free and ﬁlled symbols drug-containing conditions. n   2–4 cells per condition.48 Flecainide Block of Mutant Heart Na  Channels
sociates from the channel (Hille, 1977a; Bean et al.,
1983).
Our results thus implicate a crucial role of the inac-
tivated state of the Na  channel in the development
of ﬂecainide UDB. To test if this is indeed the case,
we extended the analysis of ﬂecainide UDB to a series
of Na  channel mutations that alter the voltage-depen-
dence of channel availability and that have been de-
scribed in more detail in other studies. As predicted,
we found signiﬁcantly greater UDB by ﬂecainide for
mutations that cause negative shifts in the voltage-
dependence of channel availability (inactivation) and
less UDB for mutations shift availability in the posi-
tive direction. Furthermore, mutations that cause
negative shifts in channel availability (DG, YH) also
markedly slow the recovery from drug block of these
channels. These data, summarized in Tables I and II,
support the hypothesis that the development of UDB
by ﬂecainide is due to preferential block of inacti-
vated channels.
DISCUSSION
Molecular Determinants of Flecainide Block
Blockade of voltage-dependent Na  channels has long
been recognized as a therapeutic approach to the man-
agement of many cardiac arrhythmias, but with consid-
erable risk of toxic side effects (Rosen et al., 1975). The
discovery that mutant forms of Na  channels linked to
inherited human cardiac arrhythmias might make dis-
tinct targets for Na  channel blocking drugs (An et al.,
1996; Wang et al., 1997; Dumaine and Kirsch, 1998;
Kambouris et al., 2000; Nagatomo et al., 2000; Viswan-
athan et al., 2001) has stimulated reinvestigation of
the molecular determinants of Na  channel block-
ade in the heart. In this study, we have used several dis-
ease-linked Na  channel mutations that alter key bio-
physical properties and drug sensitivity of encoded
channels in order to elucidate the mechanism by which
mutation-induced changes in channel properties un-
derlie altered apparent afﬁnity of drug block. We fo-
TABLE I
Parameters Describing the Time Course of Recovery from Flecainide UDB
Fraction of steady-state
recovered current
A1 (fraction
recovering at  1)  1
A2 (fraction
recovering at  2)  2
ms ms
WT control 1 0.87 6.96 0.28 290
WT flecainide 0.45 0.31 103 0.17 2,530
1 0.45 148 0.67 42,700
DG control 1 0.83 7.45 0.30 298
DG flecainide 0.15 0.097 37.4 0.07 4,240
1 0.11 49.6 0.91 138,000
YH control 1 0.90 6.11 0.17 172
YH flecainide 0.19 0.31 61.2 0.08 3,820
1 0.29 249 0.85 173,000
YC control 1 0.64 6.19 0.31 384
YC flecainide 0.49 0.39 21.9 0.39 406
1 0.40 185 0.57 48,300
TABLE II
Relationship between Mutation-induced Shift in Channel Availability
 V1/2 for inactivation    V1/2 for activation   UDB percentage at 5 Hz Linked disease
mV mV
WT 50.94   2.97 (n   4)
Y1795H  10.50   0.8a (n   5) 0.9   0.3 (n   5) 73.75   3.04a (n   4) BrS (Rivolta et al., 2001)
D1790G  10.21   0.37a (n   6) 1.4   0.5 (n   6) 79.56   2.96a (n   5) LQT-3 (Benhorin et al., 1998)
1885stop  11.0   0.6a (n   9) 0.9   0.4 (n   12) 80.0   2.0a (n   3)
Y1795E  10.40   0.9a (n   6) 1.7   1.4 (n   6) 72.0   1.20a (n   4)
Y1795R  10.56   1.3a (n   6) 2.1   0.5 (n   6) 65.0   5.10b (n   3)
Y1795C  2.80   0.4 (n   8)  1.0   0.4 (n   8) 49.33   0.16 (n   4) LQT-3 (Rivolta et al., 2001)
E1295K 5.2   0.2a (n   7) 3.4   0.3b (n   7) 37.0   4.97b (n   4) LQT-3 (Abriel et al., 2001)
Data are mean   SEM.
aP   0.01.
bP   0.05.49 Liu et al.
cused on the Na  channel blocker ﬂecainide, which is
distinguished in its UDB activity, because it has been
shown to be very effective in correcting QT prolonga-
tion in carriers of some LQT-3 mutations (Benhorin et
al., 2000; Windle et al., 2001), and is also used clinically
to detect candidates for Na  channel mutations under-
lying BrS (Brugada et al., 2000). From our experimen-
tal data, we conclude that ﬂecainide UDB occurs as a
consequence of stabilization of the drug-bound inacti-
vated state of the channel after access to a drug binding
site that is permitted only after channels open, and that
disease-linked mutations that alter the voltage-depen-
dence of inactivation alter ﬂecainide UDB.
Voltage-dependent block of Na  channels by local
anesthetics and related drugs has been well described
within the framework of the modulated receptor hy-
pothesis which proposes that allosteric changes in a
drug receptor occur when changes in voltage in-
duce changes in channel conformation (states) (Hille,
1977a; Hondeghem and Katzung, 1977). High-afﬁnity
binding of the local anesthetics lidocaine and mexile-
tine to the inactivated state of the Na  channel has been
shown to require two critical amino acid residues, Phe-
1764 and Tyr-1771, located in the IVS6 transmembrane
segment in the brain IIA and cardiac Na  channels
(Ragsdale et al., 1994, 1996; Li et al., 1999; Weiser et al.,
1999). Evidence for binding to the inactivated state was
provided in part by the voltage-dependence of fre-
quency-dependent block. The voltage-threshold for
lidocaine binding was found to coincide with the volt-
age dependence of channel transitions from closed
(rested) to inactivated states. In contrast, the threshold
for ﬂecainide UDB was much closer to the voltage that
promotes channel activation (25 mV more positive
than lidocaine), corresponding to transitions from
closed (rested) to open states (Ragsdale et al., 1996).
Thus, these data suggested that, while lidocaine prefer-
entially interacted with inactivated channels, ﬂecainide
was more likely to bind with high afﬁnity to open chan-
nels, consistent with earlier investigations in native cells
(Anno and Hondeghem, 1990).
Inherited Mutations Reveal the Role of Channel Openings in 
Use-dependent Block of Na  Channels by Flecainide
Our results indicate that the threshold for ﬂecain-
ide UDB closely parallels that for channel activation
(Fig. 3), but additional experiments in this study are
not consistent with open state block. The potency
of ﬂecainide UDB did not decrease with mutation-
induced shortening of channel MOT, but instead was
increased by mutations that shortened MOT. In contrast,
all mutations that decreased channel availability at neg-
ative potentials (caused hyperpolarizing shifts in the
voltage-dependence of channel inactivation) increased
the sensitivity of the encoded channels to ﬂecainide
block. Most convincingly, the E1295K mutation, which
has an opposite effect on the voltage-dependence of in-
activation (Abriel et al., 2001), reduces the channel
sensitivity to ﬂecainide UDB (Table II). The simplest
interpretation of these results is that ﬂecainide inter-
acts preferentially with inactivated channels, but that
channel openings are required for drug access to its re-
ceptor site. The results shown in Fig. 4 C (WT vs. YC)
support the view that channel opening is required for
drug access because the onset of drug block is faster for
channels with prolonged MOT (YC). A similar conclu-
sion has recently been reached regarding mexiletine
block of myotonia and periodic paralysis mutations
of skeletal muscle sodium channels (Desaphy et al.,
2001). An interesting observation is that the drug disso-
ciation rate during steady-state pulse trains (Fig. 4 C) is
apparently much faster than is observed in the recovery
from drug block at hyperpolarized potentials (Fig. 7),
because if recovery from open inactivated channels
were as slow as recovery from closed inactivated chan-
nels, block during repetitive pulse trains would in-
crease until all channels were blocked (Chernoff, 1990;
Chernoff and Strichartz, 1990). This suggests ﬂecainide
cannot leave its binding site as easily from closed inacti-
vation states as it can from open inactivation states.
Ionized Flecainide may Limit Access to Sites
Lidocaine has a pKa of 7.6–8.0 and thus may be up to
50% neutral at physiologic pH (Hille, 1977b; Strichartz
et al., 1990). In contrast, ﬂecainide has a pKa of  9.3,
leaving  1% neutral at pH 7.4 (Hille, 1977b; Strichartz
et al., 1990). Thus, one possibility underlying differ-
ences in the voltage-dependence of ﬂecainide- and
lidocaine-induced modulation of cardiac Na  channels
is restricted access to a common site that is caused by
the ionized group of ﬂecainide. Channel opening
would then be a prerequisite for ﬂecainide, but not
lidocaine, UDB. Our data, consistent with this scheme,
suggest that ﬂecainide, like lidocaine, interacts prefer-
entially with inactivated channels and that mutations
that promote inactivation (shift channel availability
in the hyperpolarizing direction) enhance ﬂecainide
UDB. Interestingly, in a study of the molecular determi-
nants of local anesthetic block of sodium channels,
Ragsdale et al. (1996) reported weak functional overlap
of in the effects of mutations that disrupt lidocaine and
ﬂecainide block of brain Na  channels.
Recent studies of both ﬂecainide and lidocaine block
of cardiac sodium channels have revealed roles of an
intermediate inactivated state (Chen et al., 2000; Kam-
bouris et al., 2000; Viswanathan et al., 2001). Although
similar to the state-dependent interactions we describe,
there are key differences between the voltage-depen-
dence of ﬂecainide block we describe (block due to
open state inactivation) and previously described block50 Flecainide Block of Mutant Heart Na  Channels
that develops over voltages below the threshold for
channel opening (Viswanathan et al., 2001). Differ-
ences between these mechanisms may be due to drug
interactions via multiple pathways. Clearly, UDB re-
ported in this study demands that channels ﬁrst open
before drug block occurs and hence cannot occur via
the closed inactivated transition.
Flecainide Sensitivity Is Mutation-, but not Disease-, speciﬁc
The mutations used in the present study were discov-
ered by genetic analysis of both LQT-3 and BrS patients
(Benhorin et al., 1998; Abriel et al., 2001; Rivolta et
al., 2001), but mutation-altered ﬂecainide sensitivity
segregates with channel but not disease phenotype.
This is most apparent in comparing the sensitivities
of Y1795H (BrS) and D1790G (LQT-3) channels to
ﬂecainide: both are fourfold more sensitive to ﬂecain-
ide than WT channels (Fig. 2), despite being linked to
two different diseases. On the other hand, LQT-3
Y1795C channels respond to ﬂecainide block with the
same sensitivity as WT channels, but are fourfold less
sensitive than the LQT-3 mutant D1790G channels to
ﬂecainide block. Clearly in the case of the two inher-
ited arrhythmias, LQT-3 and BrS, it is possible for one
(ﬂecainide) drug to cross disease boundaries and have
similar pharmacological proﬁles for mutant channels
that are distinct from the proﬁles of WT channels.
Thus, it is not surprising that in some cases drug-
induced effects in patients may be similar for some BrS
and/or LQT-3 mutations (Priori et al., 2000; Cerrone
et al., 2001).
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